Oncology News | pharmaphorum

News

NICE says yes to BeiGene's Brukinsa after Scottish nay

BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM

News

Takeda farms out cancer drug alisertib to Puma Biotech

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself.<

News

Regeneron's bispecific REGN1979 shows promise in advanced NH...

Regeneron’s bispecific antibody REGN1979 has produced some enticing results in an early-stage non-Hodgkin lymphoma trial, including in patients who had previously been treated with CAR-T th

News

Opdivo set to take on Keytruda in adjuvant melanoma

Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea

News

ESMO: Amgen reveals Lumakras data as rival looms in rear-vie...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in

News

ESMO: TIL therapy improves on Yervoy in melanoma trial

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno

NICE says yes to BeiGene's Brukinsa after Scottish nay

Takeda farms out cancer drug alisertib to Puma Biotech

Regeneron's bispecific REGN1979 shows promise in advanced NH...

Opdivo set to take on Keytruda in adjuvant melanoma

ESMO: Amgen reveals Lumakras data as rival looms in rear-vie...

ESMO: TIL therapy improves on Yervoy in melanoma trial

J&J abandons trial of atopic dermatitis drug

How to meet your physicians where they are online

News

Editor's Picks